Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 13 for:    tas-102
Previous Study | Return to List | Next Study

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Taiho Oncology, Inc.
ClinicalTrials.gov Identifier:
NCT01874522
First received: June 4, 2013
Last updated: May 27, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.


Condition Intervention Phase
Advanced Solid Tumors (Excluding Breast Cancer)
Drug: TAS-102 tablets
Drug: TAS-102 oral solution
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Resource links provided by NLM:


Further study details as provided by Taiho Oncology, Inc.:

Primary Outcome Measures:
  • Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (Cmax) [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (AUC0-last) [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (AUC0-inf ) [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.


Secondary Outcome Measures:
  • Tmax of FTD, TPI, and metabolites of FTD following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • T1/2 of FTD, TPI, and metabolites of FTD following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • CL/F of FTD and TPI following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • Vd/F of FTD and TPI following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • Cmax of metabolites of FTD following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • AUC0-last of metabolites of FTD following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • AUC0-inf of metabolites of FTD following administration of TAS 102 tablet and oral solution [ Time Frame: Day 1 of Periods 1, 2, and 3 ] [ Designated as safety issue: No ]
    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

  • Safety monitoring including adverse events, vital signs, and laboratory assessments [ Time Frame: Through 30 days following last administration of study medication or until initiation of new anticancer treatment ] [ Designated as safety issue: Yes ]
    Standard safety monitoring and grading using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) will be used.

  • Tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Every 8 weeks during the extension period through Cycle 6 (ie, through 24 weeks). Thereafter, assessments will be performed at least every 12 weeks according to site standard of care, until at least one of the treatment discontinuation criteria is met. ] [ Designated as safety issue: No ]

Estimated Enrollment: 42
Study Start Date: July 2013
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAS-102 tablets Drug: TAS-102 tablets

Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.

Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Experimental: TAS-102 oral solution Drug: TAS-102 oral solution
60 mg/dose, orally, up to 2 single doses separated by 1-week washout

Detailed Description:

This is a Phase 1, open-label, randomized, 2-sequence, 3-period crossover study evaluating the relative bioavailability of TAS-102 tablets compared to an oral solution in patients with advanced solid tumors. This study will be conducted in 2 parts. The crossover bioavailability part will be followed by an extension conducted with TAS-102 tablets only.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Has provided written informed consent
  2. Has advanced solid tumors (excluding breast cancer) for which no standard therapy exists
  3. ECOG performance status of 0 or 1
  4. Is able to take medications orally
  5. Has adequate organ function (bone marrow, kidney and liver)
  6. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.

Exclusion Criteria:

  1. Has had certain other recent treatment e.g. anticancer therapy, received investigational agent, within the specified time frames prior to study drug administration
  2. Certain serious illnesses or medical condition(s)
  3. Has had either partial or total gastrectomy
  4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies
  5. Known sensitivity to TAS-102 or its components
  6. Is a pregnant or lactating female
  7. Refuses to use an adequate means of contraception (including male patients)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01874522

Locations
United States, Arizona
Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
Sponsors and Collaborators
Taiho Oncology, Inc.
Investigators
Principal Investigator: Daniel Von Hoff, MD Scottsdale Healthcare
  More Information

No publications provided

Responsible Party: Taiho Oncology, Inc.
ClinicalTrials.gov Identifier: NCT01874522     History of Changes
Other Study ID Numbers: TPU-TAS-102-104
Study First Received: June 4, 2013
Last Updated: May 27, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Taiho Oncology, Inc.:
Advanced solid tumors (excluding breast cancer) for which no standard therapy exists

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014